Last reviewed · How we verify
NCT03001349
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
EARLY_PHASE1 trial testing Computed Tomography in Meningioma in 4 participants. Terminated before completion.
5 February 2021
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 4 |
| Start date | 16 May 2017 |
| Primary completion | 5 February 2021 |
| Estimated completion | 5 February 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Computed Tomography
- Gallium Ga 68-Edotreotide — full drug profile →
- Positron Emission Tomography
Conditions studied
- Meningioma — all drugs for Meningioma →
- Metastatic Well Differentiated Neuroendocrine Neoplasm — all drugs for Metastatic Well Differentiated Neuroendocrine Neoplasm →
- Multiple Endocrine Neoplasia Type 1 — all drugs for Multiple Endocrine Neoplasia Type 1 →
- Neuroendocrine Neoplasm — all drugs for Neuroendocrine Neoplasm →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
Eligibility, any sex, with Meningioma or Metastatic Well Differentiated Neuroendocrine Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial studies how well gallium Ga 68-edotreotide (68Ga-DOTA-TOC) positron emission tomography (PET)/computer tomography (CT) works in imaging participants with neuroendocrine tumors. 68Ga-DOTA-TOC is used as a tracer chemical during PET/CT scans. Diagnostic procedures, such as 68Ga-DOTA-TOC PET/CT, may help find and diagnose neuroendocrine tumors.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Hormone therapies in meningioma-where are we?
Miyagishima DF, Moliterno J, Claus E, Günel M. · · 2023 · cited 17× · PMID 36418843 · DOI 10.1007/s11060-022-04187-1
Verify or expand the search:
- PubMed search for NCT03001349
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Computed Tomography
Trials testing the same drug.
- NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
- NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
- NCT07147231 — Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem · Phase 1, PHASE2 · recruiting
- NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
Other recruiting trials for Meningioma
Currently open trials in the same condition.
- NCT06831461 — Proton Versus Photon Radiotherapy in Adults With Primary Brain Tumors · NA · recruiting
- NCT07044076 — Translation and Validation of the MQOL Self-questionnaire Into French for Assessing Quality of Life in Patients With Men · recruiting
- NCT06132685 — Post-Operative Dosing of Dexamethasone in Patients With Brain Tumors After a Craniotomy, PODS Trial · Phase 2 · recruiting
- NCT06752096 — Robot-Assisted Neurovascular Intervention · NA · recruiting
- NCT06830356 — Somatostatin Receptor PET Imaging to Guide Radiotherapy Dose Escalation in High Risk Meningiomas. · NA · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03001349 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 15 February 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03001349.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing